This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Naftidrofuryl is a peripheral vasodilator indicated in the treatment of chronic venous ulcers.

Generic Name
Naftidrofuryl
DrugBank Accession Number
DB13588
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 383.5237
Monoisotopic: 383.246043927
Chemical Formula
C24H33NO3
Synonyms
  • Nafronyl
  • Naftidrofurilo
  • Naftidrofuryl
  • Naftidrofurylum
External IDs
  • LS 84
  • LS-84

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Naftidrofuryl.
AcenocoumarolThe risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Naftidrofuryl.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Naftidrofuryl.
AclidiniumNaftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Naftidrofuryl.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Naftidrofuryl.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Naftidrofuryl.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Naftidrofuryl.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Naftidrofuryl.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Nafronyl oxalate5ADB8D93883200-06-4SSAJNPNVUYMUCI-UHFFFAOYSA-N
International/Other Brands
Dubimax / Dusodril / Gevatran / Iridus / Praxilene

Categories

ATC Codes
C04AX21 — Naftidrofuryl
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Fatty acid esters / Tetrahydrofurans / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Oxacyclic compounds / Monocarboxylic acids and derivatives / Dialkyl ethers / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether / Ether / Fatty acid ester / Fatty acyl
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
42H8PQ0NMJ
CAS number
31329-57-4
InChI Key
KBAFPSLPKGSANY-UHFFFAOYSA-N
InChI
InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 3-(naphthalen-1-yl)-2-[(oxolan-2-yl)methyl]propanoate
SMILES
CCN(CC)CCOC(=O)C(CC1CCCO1)CC1=CC=CC2=C1C=CC=C2

References

General References
  1. DIMDI Drug Product Information: Naftilong (naftidrofuryl oxalate) extended-release capsules [Link]
  2. EMC Summary of Product Characteristics: Naftidrofuryl oral capsules [Link]
  3. AIFA: Praxilene (Naftidrofuryl) Tablet [Link]
ChemSpider
4264
BindingDB
50347133
RxNav
7236
ChEBI
91817
ChEMBL
CHEMBL1620794
Wikipedia
Naftidrofuryl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral100 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral
Tablet, extended releaseOral100 MG
Tablet, coated
Capsule, extended releaseOral200 MG
Capsule, extended releaseOral100 MG
Tablet200 MG
Tablet, film coatedOral100 MG
Tablet, film coatedOral200 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000636 mg/mLALOGPS
logP4.73ALOGPS
logP4.58ChemAxon
logS-5.8ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity113.77 m3·mol-1ChemAxon
Polarizability44.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Mass Spectrum (Electron Ionization)MSsplash10-000i-9100000000-d75c1dd41b1e807c5df5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:44 / Updated at May 29, 2021 18:11